Top in GI: Refractory celiac disease guidance; constipation treatment
Click Here to Manage Email Alerts
The American Gastroenterological Association recently updated its guidance for refractory celiac disease, which features a step-by-step approach for following a gluten-free diet and information on tests and treatments.
Among its recommendations, the American Gastroenterological Association (AGA) said that corticosteroids such as open-capsule budesonide or prednisone should be used as first-line therapy in type 1 or type 2 refractory celiac disease. It was the top story in gastroenterology last week.
Other top stories were based on presentations from the American College of Gastroenterology (ACG) Annual Scientific Meeting. In one presentation, researchers reported that a vibrating capsule was safe and well-tolerated in patients with chronic idiopathic constipation.
Read these and more top stories in gastroenterology below:
AGA releases 10 best practice statements for management of refractory celiac disease
In an expert review published in Gastroenterology, AGA provided updated guidance for the diagnosis and management of refractory celiac disease, including supportive and therapeutic treatment options and recommendations for monitoring. Read more.
Vibrating capsule safe, well-tolerated, easy to use in chronic idiopathic constipation
An orally ingested vibrating capsule was found to be safe, well-tolerated and easy to use for the treatment of chronic idiopathic constipation, according to data presented at the ACG Annual Scientific Meeting. Read more.
Follow-up surveillance within 5 years may detect post-colonoscopy CRC
Recommended surveillance interval was the most important modifiable risk factor for post-colonoscopy colorectal cancer at 3 years, data show. Read more.
IBD specialists, nonphysician practitioners have greater EHR burden in gastroenterology
In gastroenterology practices, inflammatory bowel disease specialists and nonphysician practitioners experienced increased electronic health record burden, according to a presenter at the ACG Annual Scientific Meeting. Read more.
Holding IBD therapy for COVID-19 vaccine ‘does not impact’ infection, hospitalization risk
Withholding immunosuppressive therapy prior to or following COVID-19 vaccination did not impact the rate of breakthrough infection or hospitalizations in patients with inflammatory bowel disease, noted a presenter. Read more.